Dr. Shadi Farhangrazi has been recognized and nominated for Northern Power House Ethnic Minority Powerlist Thought Leaders. This is a great recognition for Dr. Farhangrazi's tireless work on advancing therapies for neurodegenerative and rare paediatric diseases, promoting health equity and improving educational outcomes. 

December 2024

SMDG scientists, Professor Moein Moghimi, pioneering scientist and inventor of our Peptide Therapeutic Platforms and our esteemed Dr. Christy Hunter have been named to the List of World’s Most Cited researchers. Every year, Stanford University and Elsevier’s publish their “Updated Science-Wide Author Databases of Standardized Citation Indicators”. This prestigious database highlights top scientists globally, showcasing their impact across 22 scientific disciplines and 174 sub-fields and provides career long data (to the end-of-2023 and single year (2023) data). This prestigious list has named Professor Moghimi among the world’s leading top 0.036% of scientists (only 8000 scientists in the world) on a career long basis.  He has been recognized as #4 (#9 including those retired and inactive) scientist and researcher in the UK in Pharmacology and Pharmacy, and #46 (including those retired and inactive) in the world among 148,458 scientists in Pharmacology and Pharmacy.  Dr. Hunter has been recognized among the top 2% of the scientists in all fields, across 22 scientific disciplines and 174 sub-fields.

September 2024

SMDG team welcomes Mr. Theo Godfrey. Mr. Godfrey is a corporate and venture capital lawyer and a Partner in the London office of CMS Cameron McKenna Nabarro Olswang LLP. Much of his practice is focussed on transactions in the life sciences sector. He is an advocate for research and funding for rare paediatric diseases.

September 2024

SMDG team welcomes Dr. Christy Hunter as the Director of Chemistry. Dr Hunter has over 25 years of experience in Drug Delivery and Nanomedicine. "We are excited to welcome Dr. Christy Hunter, an accomplished and well-known chemist who has an impressive track record of scientific work over the last 25 years". Dr. Farhangrazi, CEO of SMDG.

August 2024

SMDG is a finalist in two categories at the Pharma Industry Award UK 2024. SMDG is a finalist in the category,  Research and Development Achievement Award: S. M. Discovery - Pioneering Therapeutic Platforms, NanoLigand Carriers, and Dr. Shadi Farhangrazi, CEO, has been selected as one of the finalists for the Women in Pharma Award. 

August 2024

Professor Moein Moghimi, our Co-Founder and inventor of our therapeutic platforms has been appointed the Editor in Chief of the prestigious journal of "Drug Delivery".  A Taylor and Francis Journal, Drug Delivery publishes open access peer-reviewed research on the development and application principles of drug delivery and targeting at molecular, cellular, and higher levels.   Drug Delivery aims to serve both the academic and industrial communities and publishes papers on the following topics:  All drug delivery systems, including oral, pulmonary, nasal, parenteral and transdermal delivery,   All modes of drug entry, such as controlled release systems; Microcapsules, liposomes, vesicles, and macromolecular conjugates,  Antibody targeting, Protein/peptide delivery, DNA, oligonucleotide and siRNA delivery.

April 2024

SMDG has been selected to participate in the Discovery Park, Spark Femtech and Women's Health cohort programme. This is the first of its kind programme in the UK focusing on companies developing therapies for women's health. This is in recognition of our innovative and pioneering work on neurological diseases and women's health.

April 2024

SMDG has appointed Dr Zsuzsanna Devecseri, M.D., MBA, to its Board of Directors (Board). Dr. Devecseri is a highly successful biopharmaceutical business executive who brings extensive leadership experience to SMDG as it progresses towards an important critical period of growth. Zsuzsanna Devecseri, MD, MBA, is the Global Head, Medical Affairs, Oncology, Novartis, 

March 2024

Dr Shadi Farhangrazi, our CEO, has been named one of recipients of the  SME News- CEO of the Year Awards.
Most Innovative Life Saving Therapy CEO – UK,  

March 2024

Dr. Shadi Farhangrazi, our CEO, has been invited to join a fireside chat with Dr. Angela Cacace and Dr. Katie Digiananitonio from Arvinas, a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics, based in New Haven, Connecticut, USA.  The virtual conversation will be held on March 8th in commemoration of International Women's Day and will be attended by hundreds of Arvinas employees. The discussion will focus on Dr. Farhangrazi's journey as a scientist and woman.  

March 2024